Posttransplant information and incidence of cardiac toxicity
| (A) Main posttransplant information . | Overall N = 416 . | Allo-HCT with PTCY-based prophylaxis n = 258 . | Allo-HCT with other prophylaxis n = 158 . | P value . |
|---|---|---|---|---|
| Engraftment information | ||||
| Median days neutrophil engraftment (IQR) | 18 (15-22) | 20 (17-23) | 16 (14-18) | .001 |
| Median days platelet engraftment (IQR) | 14 (11-23) | 19 (13-28) | 12 (10-14) | .001 |
| Primary graft failure | 7 (1.6) | 6 (2.3) | 1 (0.6) | .268 |
| Second allograft∗ | 4 (0.9) | 4 (1.5) | 0 | .302 |
| Cumulative incidence GVHD | ||||
| Grade 2-4 acute GVHD at day +100 | 28.9 (24.6-33.3) | 24.1 (19.0-29.5) | 36.7 (29.2-44.2) | .001 |
| Grade 3-4 acute GVHD at day +100 | 8.9 (6.4-11.9) | 6.2 (3.7-9.6) | 13.3 (8.5-19.1) | .007 |
| Moderate/severe chronic GVHD at 2-y | 22.7 (18.4-27.3) | 12.0 (7.9-17.0) | 37.1 (29.3-45.0) | <.001 |
| Main outcome information∗ | - | |||
| Relapse | 105 (25.2) | 58 (22.4) | 47 (29.7) | - |
| Dead | 134 (32.2) | 74 (28.6) | 60 (37.9) | |
| Main causes of dead | ||||
| Relapse | 63 (15.1) | 29 (11.2) | 34 (21.5) | |
| Infection | 30 (7.2) | 22 (8.5) | 8 (5.0) | |
| Graft failure | 8 (1.9) | 6 (2.3) | 2 (1.2) | |
| GVHD | 18 (4.3) | 7 (2.7) | 11 (6.9) | |
| ECE | 2 (0.4) | 1 (0.3) | 1 (0.6) | |
| Other | 13 (3.1) | 9 (3.4) | 4 (2.5) | |
| Main posttransplant outcomes (% [95% CI])† | ||||
| 2-y OS | 65.5 (60.5-70.1) | 67.9 (61.3-73.6) | 61.7 (536-68.8) | .193 |
| 2-y relapse-free survival | 55.2 (50.1-60.1) | 55.8 (49.0-62.1) | 53.5 (45.4-61.0) | .528 |
| 2-y NRM | 17.9 (14.2-21.8) | 18.7 (14.0-23.9) | 16.5 (11.2-22.8) | .546 |
| 2-y cumulative incidence of relapse | 26.9 (22.6-31.4) | 25.5 (19.9-31.4) | 29.9 (22.9-37.2) | .207 |
| B) Early cardiac toxicity | ||||
| Total events: | 35 (8.4) | 29 (11.2) | 6 (3.7) | .010 |
| Cumulative incidence of tardiac toxicity (% [95% CI]) | ||||
| Day +180 | 8.4 (6.0-11.4) | 11.3 (7.8-15.5) | 3.8 (1.6-7.7) | .007 |
| Main related information: | N = 35 | N = 29 | N = 6 | |
| Type of cardiac toxicity | ||||
| Arrhythmia | 8 (22.8) | 7 (25.0) | 1 (16.7) | .580 |
| Pericarditis and/or pericardial Effusion | 11 (31.4) | 9 (31.0) | 2 (33.3) | .629 |
| Heart failure | 13 (37.1) | 11 (37.9) | 2 (33.3) | .608 |
| Ischemia | 1 (3.0) | 0 | 1 (16.7) | .177 |
| Other | 2 (5.7) | 2 (5.1) | 0 | .682 |
| Grade | ||||
| 1-2 | 21 (60.0) | 18 (62.0) | 3 (50) | .456 |
| 3-4 | 12 (34.2) | 10 (34.4) | 2 (33.3) | .311 |
| 5 | 2 (5.87) | 1 (3.4) | 1 (16.7) | .318 |
| Median of days to the event (IQR) | ||||
| Early cardiac toxicity | 27 (12-90) | 24 (13-67) | 59 (5-128) | .569 |
| Overall mortality (∗ any cause) | ||||
| 30-d mortality rate | 6 (17.1) | 3 (10.3) | 3 (50.0) | .268 |
| 100-d mortality rate | 14 (40.0) | 11 (37.9) | 3 (50.0) | .456 |
| (A) Main posttransplant information . | Overall N = 416 . | Allo-HCT with PTCY-based prophylaxis n = 258 . | Allo-HCT with other prophylaxis n = 158 . | P value . |
|---|---|---|---|---|
| Engraftment information | ||||
| Median days neutrophil engraftment (IQR) | 18 (15-22) | 20 (17-23) | 16 (14-18) | .001 |
| Median days platelet engraftment (IQR) | 14 (11-23) | 19 (13-28) | 12 (10-14) | .001 |
| Primary graft failure | 7 (1.6) | 6 (2.3) | 1 (0.6) | .268 |
| Second allograft∗ | 4 (0.9) | 4 (1.5) | 0 | .302 |
| Cumulative incidence GVHD | ||||
| Grade 2-4 acute GVHD at day +100 | 28.9 (24.6-33.3) | 24.1 (19.0-29.5) | 36.7 (29.2-44.2) | .001 |
| Grade 3-4 acute GVHD at day +100 | 8.9 (6.4-11.9) | 6.2 (3.7-9.6) | 13.3 (8.5-19.1) | .007 |
| Moderate/severe chronic GVHD at 2-y | 22.7 (18.4-27.3) | 12.0 (7.9-17.0) | 37.1 (29.3-45.0) | <.001 |
| Main outcome information∗ | - | |||
| Relapse | 105 (25.2) | 58 (22.4) | 47 (29.7) | - |
| Dead | 134 (32.2) | 74 (28.6) | 60 (37.9) | |
| Main causes of dead | ||||
| Relapse | 63 (15.1) | 29 (11.2) | 34 (21.5) | |
| Infection | 30 (7.2) | 22 (8.5) | 8 (5.0) | |
| Graft failure | 8 (1.9) | 6 (2.3) | 2 (1.2) | |
| GVHD | 18 (4.3) | 7 (2.7) | 11 (6.9) | |
| ECE | 2 (0.4) | 1 (0.3) | 1 (0.6) | |
| Other | 13 (3.1) | 9 (3.4) | 4 (2.5) | |
| Main posttransplant outcomes (% [95% CI])† | ||||
| 2-y OS | 65.5 (60.5-70.1) | 67.9 (61.3-73.6) | 61.7 (536-68.8) | .193 |
| 2-y relapse-free survival | 55.2 (50.1-60.1) | 55.8 (49.0-62.1) | 53.5 (45.4-61.0) | .528 |
| 2-y NRM | 17.9 (14.2-21.8) | 18.7 (14.0-23.9) | 16.5 (11.2-22.8) | .546 |
| 2-y cumulative incidence of relapse | 26.9 (22.6-31.4) | 25.5 (19.9-31.4) | 29.9 (22.9-37.2) | .207 |
| B) Early cardiac toxicity | ||||
| Total events: | 35 (8.4) | 29 (11.2) | 6 (3.7) | .010 |
| Cumulative incidence of tardiac toxicity (% [95% CI]) | ||||
| Day +180 | 8.4 (6.0-11.4) | 11.3 (7.8-15.5) | 3.8 (1.6-7.7) | .007 |
| Main related information: | N = 35 | N = 29 | N = 6 | |
| Type of cardiac toxicity | ||||
| Arrhythmia | 8 (22.8) | 7 (25.0) | 1 (16.7) | .580 |
| Pericarditis and/or pericardial Effusion | 11 (31.4) | 9 (31.0) | 2 (33.3) | .629 |
| Heart failure | 13 (37.1) | 11 (37.9) | 2 (33.3) | .608 |
| Ischemia | 1 (3.0) | 0 | 1 (16.7) | .177 |
| Other | 2 (5.7) | 2 (5.1) | 0 | .682 |
| Grade | ||||
| 1-2 | 21 (60.0) | 18 (62.0) | 3 (50) | .456 |
| 3-4 | 12 (34.2) | 10 (34.4) | 2 (33.3) | .311 |
| 5 | 2 (5.87) | 1 (3.4) | 1 (16.7) | .318 |
| Median of days to the event (IQR) | ||||
| Early cardiac toxicity | 27 (12-90) | 24 (13-67) | 59 (5-128) | .569 |
| Overall mortality (∗ any cause) | ||||
| 30-d mortality rate | 6 (17.1) | 3 (10.3) | 3 (50.0) | .268 |
| 100-d mortality rate | 14 (40.0) | 11 (37.9) | 3 (50.0) | .456 |